2 Biotech Stocks Wall Street Predicts Will Rally By More Than 150%

NASDAQ: SRNE | Sorrento Therapeutics Inc. News, Ratings, and Charts

SRNE – The Biotech industry has been instrumental in developing treatments for the coronavirus. The sector’s long-term potential remains solid due to the aging populating and the rising cost of healthcare. Wall Street analysts expect biotech stocks Sorrento Therapeutics (SRNE) and Catabasis Pharmaceuticals (CATB) to deliver exponential returns in the upcoming months.

The Biotech industry has been in the limelight for quite some time. Companies directly or indirectly involved in COVID-19 related products such as vaccines and medicines are ramping up their production capacities as several countries are dealing with new variants of the virus. 

Biotech companies with non-COVID drug pipelines, on the other hand, are focusing on tech integration and DNA synthesis in hopes of breakthrough development. The global biotech industry is expected to grow at a CAGR of 15.8% over the next seven years to reach $2.44 trillion by 2028.

Given this backdrop, Wall Street analysts expect the biotech stocks Sorrento Therapeutics, Inc. (SRNE) and Catabasis Pharmaceuticals, Inc. (CATB) to gain significantly in the upcoming months.

Sorrento Therapeutics, Inc. (SRNE)

SRNE is a clinical-stage and commercial biopharma company engaged in developing therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. The company operates through two segments: Sorrento Therapeutics and Scilex.

On June 24, SRNE received Emergency Use Approval and Import License from Mexico Authority COFEPRIS for its COVID-19 detection drug COVI-STIX™, which is to be launched this month. SRNE should benefit significantly from this launch.

SRNE’s total revenue increased 84.6% year-over-year to $14.26 million in the fiscal first quarter, which ended March 31. The company’s service revenue increased 192.4% from its year-ago value to $7.23 million. Its net income stood at $2.42 million, indicating a 103.5% improvement from the same period last year.

Analysts expect SRNE’s revenues to increase 237.5% year-over-year to $134.94 million in the current year. Moreover, revenue is expected to increase by 792.8% in the next year. The consensus EPS estimate of $1.71 for the next year indicates a 363.1% rise from the last year. Shares of SRNE have gained 42.4% over the past year, and 42.9% year-to-date.

Two Wall Street analysts that rated SRNE, rated it Buy. The median price target of $24.50 indicates a potential upside of 151.2% from its last closing price of $9.76. The price targets range from a low of $19.00 to a high of $30.00.

Catabasis Pharmaceuticals, Inc. (CATB)

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is engaged in the discovery, development, and commercialization of therapeutics. The company’s lead candidate is the QLS-215, a potential best-in-class plasma kallikrein monoclonal antibody in preclinical development for the treatment of Hereditary Angioedema.

CATB’s cash and cash equivalents balance rose 3,708.6% from the prior-year quarter to $121.99 million in the fiscal first quarter ended March 31, 2021. R&D expenses declined 50.9% year-over-year to $2.6 million. Net cash provided by financing activities came in at $104.26 million, indicating a 306.9% rise year-over-year.

Analysts expect the company’s EPS to improve 43.4% year-over-year in the about-to-be-reported quarter ended June 2021. Moreover, the EPS is expected to improve 64.3% in the current quarter ending September 2021. Shares of CATB have gained 2% over the past month.

Of the three Wall Street analysts that rated CATB, two rated it Buy while one rated it Hold. The median price target of $5.50 indicates a potential upside of 164.4% from its last closing price of $2.08. The price targets range from a low of $5.00 to a high of $6.00.


SRNE shares were trading at $9.50 per share on Tuesday morning, down $0.26 (-2.66%). Year-to-date, SRNE has gained 39.19%, versus a 16.48% rise in the benchmark S&P 500 index during the same period.


About the Author: Subhasree Kar


Subhasree’s keen interest in financial instruments led her to pursue a career as an investment analyst. After earning a Master’s degree in Economics, she gained knowledge of equity research and portfolio management at Finlatics. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
SRNEGet RatingGet RatingGet Rating
CATBGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

Updated: Bear Market Game Plan!

Please do not assume this bear market is over. History provides many lessons on how bear markets work and thus why the S&P 500 (SPY) could easily fall another 20% or more from current levels. That is the past. Now we need to focus on the future like how low the stocks will go...and the best trades to stay on the right side of the market action. All that and more is in Steve Reitmeister updated “Bear Market Game Plan”. Read on below for more...

:  |  News, Ratings, and Charts

2 Stocks Under $50 Worth Snapping up Right Now

With the market volatility and odds of recession perpetually increasing with every interest rate hike by the Federal Reserve, investors would be advised to load up on attractively priced stocks of businesses with robust demand and stable growth trajectory. Hence, fundamentally sound stocks Kroger (KR) and APA (APA), currently trading under $50, could be ideal investments. Keep reading…

:  |  News, Ratings, and Charts

3 Stocks You'll Want to Leave out of Your Retirement Portfolio

The stock market is experiencing wild swings amid the consecutive Federal rate hikes and deteriorating investor sentiments. Moreover, the aggressive rate hikes are raising recession concerns. Therefore, fundamentally weak stocks Uber Technologies (UBER), Workhorse Group (WKHS), and AppHarvest (APPH) might be best avoided for your retirement portfolio. Also, these stocks do not pay dividends. Read on…

:  |  News, Ratings, and Charts

The Worst Stock to Buy During Times of High Inflation

Rent the Runway (RENT) is slated to cut its workforce by 24% in the face of declining consumer spending amid soaring prices. Its subscriber count dropped in the last quarter. The stock has lost more than 70% year-to-date. Given the stubbornly high inflation, RENT might be best avoided. Keep reading…

:  |  News, Ratings, and Charts

3 Stocks You'll Want to Leave out of Your Retirement Portfolio

The stock market is experiencing wild swings amid the consecutive Federal rate hikes and deteriorating investor sentiments. Moreover, the aggressive rate hikes are raising recession concerns. Therefore, fundamentally weak stocks Uber Technologies (UBER), Workhorse Group (WKHS), and AppHarvest (APPH) might be best avoided for your retirement portfolio. Also, these stocks do not pay dividends. Read on…

Read More Stories

More Sorrento Therapeutics Inc. (SRNE) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All SRNE News